<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H2CEBF3498C934FF18E51C42D03736791" public-private="public" bill-type="olc"> 
<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>114 HR 2424 IH: 21st Century Cures Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2015-05-19</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code> 
<congress>114th CONGRESS</congress> <session>1st Session</session> 
<legis-num>H. R. 2424</legis-num> 
<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber> 
<action> 
<action-date date="20150519">May 19, 2015</action-date> 
<action-desc><sponsor name-id="S000364">Mr. Shimkus</sponsor> introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc> 
</action> 
<legis-type>A BILL</legis-type> 
<official-title>To amend the Federal Food, Drug, and Cosmetic Act with respect to training and oversight in least burdensome appropriate means concept.</official-title> 
</form> 
<legis-body id="HE6EB437D89454550B3E84EA235664148" style="OLC"> 
<section id="HC38FFE85965D4C038C4D2F10C9BEFEB1" section-type="section-one"><enum>1.</enum><header>Training and oversight in least burdensome appropriate means concept</header> 
<subsection id="HC414EC9E685F4EF989C8B55F3E5E3598"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Section 513 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360c">21 U.S.C. 360c</external-xref>) is amended by inserting after subsection (i) the following:</text> <quoted-block id="H2501321AA2EA482F9326CF4FF753431C" style="OLC"> <subsection id="H7764BAF83AB645B1B205BB1F4FE07220"><enum>(j)</enum><header>Training and oversight in least burdensome appropriate means concept</header><text display-inline="yes-display-inline"></text> 
<paragraph id="H4BBB0A03B83B410AB1211D132BECA0B8"><enum>(1)</enum><header>Training</header><text display-inline="yes-display-inline">Each employee of the Food and Drug Administration who is involved in the review of premarket submissions under section 515 or section 510(k), including supervisors, shall receive training regarding the meaning and implementation of the least burdensome appropriate means concept in the context of the use of that term in subsections (a)(3)(D) and (i)(1)(D) of this section and in section 515(c)(5).</text></paragraph> <paragraph id="H37B6283A3AF444BCB2207CB2E1F74C4B"><enum>(2)</enum><header>Guidance documents</header> <subparagraph id="H8067B4D911B64071AFD793D4C9522C6F"><enum>(A)</enum><header>Draft updated guidance</header><text display-inline="yes-display-inline">Not later than 12 months after the date of enactment of the <short-title>21st Century Cures Act</short-title>, the Secretary shall issue a draft guidance document updating the October 4, 2002, guidance document entitled <quote>The Least Burdensome Provision of the FDA Modernization Act of 1997: Concept and Principles; Final Guidance for FDA and Industry</quote>.</text></subparagraph> 
<subparagraph id="H4D82123FA42446A8A7F8F633CA71E1B0"><enum>(B)</enum><header>Meeting of stakeholders</header><text>In developing such draft guidance document, the Secretary shall convene a meeting of stakeholders to ensure a full record to support the publication of such document.</text></subparagraph></paragraph> <paragraph id="HABD88A5F196344EAA55592A5DDF9E4EA"><enum>(3)</enum><header>Ombudsman audit</header><text display-inline="yes-display-inline">Not later than 18 months after the date of issuance of final version of the draft guidance under paragraph (2), the ombudsman for the organizational unit of the Food and Drug Administration responsible for the premarket review of devices shallâ€”</text> 
<subparagraph id="H96CC72088EC14113BD7D4DED9D712E88"><enum>(A)</enum><text>conduct, or have conducted, an audit of the training described in paragraph (1); and</text></subparagraph> <subparagraph id="H7BDF178F3C7449BEA4CD9B48CC34F368"><enum>(B)</enum><text>include in such audit interviews with a representative sample of persons from industry regarding their experience in the device premarket review process.</text></subparagraph></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></subsection> 
<subsection id="H0969720C81814B4DA45E852A5CBB3D79"><enum>(b)</enum><header>Additional information regarding premarket applications</header><text display-inline="yes-display-inline">Subsection (c) of section 515 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360e">21 U.S.C. 360e</external-xref>) is amended by adding at the end the follows:</text> <quoted-block style="OLC" id="H4D5ED8D4FA914F229F1A1C4D1CB89B29" display-inline="no-display-inline"> <paragraph id="HCBA8047A74254CB88FCB35868A69E86C" indent="up1"><enum>(5)</enum> <subparagraph id="HB0311B69A7D7493EAA6DF48E0C977866" display-inline="yes-display-inline"><enum>(A)</enum><text display-inline="yes-display-inline">Whenever the Secretary requests additional information from an applicant regarding an application under paragraph (1), the Secretary shall consider the least burdensome appropriate means necessary to demonstrate device safety and effectiveness, and request information accordingly.</text></subparagraph> 
<subparagraph id="H8890DF11F7F94B09B03331DB44CEC6B2" indent="up1"><enum>(B)</enum><text>For purposes of subparagraph (A), the term <quote>necessary</quote> means the minimum required information that would support a determination by the Secretary that an application provides a reasonable assurance of the safety and effectiveness of the device.</text></subparagraph> <subparagraph id="H0A7440DF185647C58F8C1674FF29BF59" indent="up1"><enum>(C)</enum><text>Nothing in this paragraph alters the standards for premarket approval of a device.</text></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></subsection></section> 
</legis-body> 
</bill> 


